Neuberger Berman Group’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.88M | Sell |
98,178
-1,367
| -1% | -$70.7K | ﹤0.01% | 987 |
|
|
2026
Q1 | $5.06M | Buy |
99,545
+5,625
| +6% | +$262K | ﹤0.01% | 980 |
|
|
2025
Q4 | $2.77M | Buy |
93,920
+14,440
| +18% | +$392K | ﹤0.01% | 1093 |
|
|
2025
Q3 | $2.05M | Buy |
79,480
+17,843
| +29% | +$498K | ﹤0.01% | 1157 |
|
|
2025
Q2 | $1.7M | Sell |
61,637
-29
| -0% | -$764 | ﹤0.01% | 1192 |
|
|
2025
Q1 | $1.75M | Buy |
61,666
+17,309
| +39% | +$614K | ﹤0.01% | 1166 |
|
|
2024
Q4 | $1.84M | Sell |
44,357
-43,144
| -49% | -$2.06M | ﹤0.01% | 1156 |
|
|
2024
Q3 | $5.85M | Sell |
87,501
-167,320
| -66% | -$15.4M | ﹤0.01% | 913 |
|
|
2024
Q2 | $30.3M | Buy |
254,821
+66,267
| +35% | +$8.39M | 0.02% | 547 |
|
|
2024
Q1 | $20.1M | Sell |
188,554
-64,732
| -26% | -$6.52M | 0.02% | 641 |
|
|
2023
Q4 | $25.2M | Buy |
253,286
+135,284
| +115% | +$11.4M | 0.01% | 732 |
|
|
2023
Q3 | $12.2M | Buy |
118,002
+36,293
| +44% | +$4.05M | 0.01% | 712 |
|
|
2023
Q2 | $9.93M | Buy |
81,709
+14,216
| +21% | +$1.9M | 0.01% | 749 |
|
|
2023
Q1 | $10.4M | Buy |
67,493
+4,565
| +7% | +$753K | 0.01% | 743 |
|
|
2022
Q4 | $11.3M | Buy |
62,928
+4,289
| +7% | +$701K | 0.01% | 727 |
|
|
2022
Q3 | $6.94M | Sell |
58,639
-1,862
| -3% | -$283K | 0.01% | 812 |
|
|
2022
Q2 | $8.65M | Buy |
60,501
+26,761
| +79% | +$3.83M | 0.01% | 778 |
|
|
2022
Q1 | $5.82M | Buy |
33,740
+1,649
| +5% | +$278K | ﹤0.01% | 926 |
|
|
2021
Q4 | $7.71M | Sell |
32,091
-26,983
| -46% | -$7.89M | 0.01% | 881 |
|
|
2021
Q3 | $22M | Sell |
59,074
-5,407
| -8% | -$1.99M | 0.02% | 655 |
|
|
2021
Q2 | $15M | Buy |
64,481
+29,981
| +87% | +$5.36M | 0.01% | 758 |
|
|
2021
Q1 | $4.5M | Buy |
34,500
+21,845
| +173% | +$3.17M | ﹤0.01% | 972 |
|
|
2020
Q4 | $1.31M | Sell |
12,655
-158,500
| -93% | -$16M | ﹤0.01% | 1191 |
|
|
2020
Q3 | $12.1M | Buy |
171,155
+46,679
| +38% | +$3.25M | 0.01% | 694 |
|
|
2020
Q2 | $7.99M | Buy |
124,476
+3,988
| +3% | +$218K | 0.01% | 763 |
|
|
2020
Q1 | $3.61M | Sell |
120,488
-519,718
| -81% | -$12M | 0.01% | 838 |
|
|
2019
Q4 | $12.5M | Buy |
640,206
+200
| +0% | +$3.55K | 0.01% | 698 |
|
|
2019
Q3 | $10.2M | Sell |
640,006
-748,108
| -54% | -$11.1M | 0.01% | 713 |
|
|
2019
Q2 | $20.3M | Buy |
1,388,114
+683,159
| +97% | +$14.7M | 0.02% | 597 |
|
|
2019
Q1 | $14.3M | Sell |
704,955
-242,070
| -26% | -$4.49M | 0.02% | 667 |
|
|
2018
Q4 | $14.5M | Buy |
+947,025
| New | +$15.6M | 0.02% | 650 |
|
Other funds holding MRNA
TP
Neuberger Berman Group's MRNA Position: Q2 2026 in Review
Neuberger Berman Group reduced its Moderna (MRNA) stake by 1.4% in Q2 2026, selling an estimated $70.7K and leaving 98,178 shares worth $6.88M. The position accounts for ﹤0.01% of the portfolio, ranked #987.
Neuberger Berman Group first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. The position peaked at $30.3M in Q2 2024. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Neuberger Berman Group held 98,178 shares of Moderna worth $6.88M as of Q2 2026.
- Neuberger Berman Group sold 1,367 Moderna shares in Q2 2026, an estimated $70.7K.
- Moderna made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #987 holding.
- Neuberger Berman Group first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
- Neuberger Berman Group's Moderna position peaked at $30.3M in Q2 2024.
- 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.